NervGen Pharma Corp.

Recent News

  • NervGen Pharma Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two ...

    2019-09-06 8:30 AM ET
  • NervGen Pharma's Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper

    Vancouver, British Columbia--(Newsfile Corp. - July 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen's ...

    2019-07-10 9:00 AM ET
  • NervGen Amends Investor Relations Agreement

    Vancouver, British Columbia--(Newsfile Corp. - July 5, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of ...

    2019-07-05 5:00 PM ET
  • NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination

    Vancouver, British Columbia--(Newsfile Corp. - June 26, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond ...

    2019-06-26 9:00 AM ET
  • NervGen Pharma Announces Upgrade to the OTCQX Best Market in the U.S.

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares ...

    2019-06-10 7:00 AM ET
  • NervGen Pharma Presenting at the 9th Annual LD Micro Invitational

    Vancouver, British Columbia--(Newsfile Corp. - June 4, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma's President ...

    2019-06-04 3:30 PM ET
  • NervGen Pharma Engages Torrey Hills Capital for Investor Relations

    Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San ...

    2019-06-03 8:30 AM ET
  • NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, ...

    2019-05-30 9:00 AM ET